BCL2 and acute myeloid leukemia: Recently, BH3 mimetic drugs that inhibit individual prosurvival family members have been developed to promote the apoptosis of cancer cells,46 and the BCL-2 inhibitor venetoclax is being used in combination therapy to treat AML.47